Display options
Cite
Nico D, Gomes DC, Palatnik-de-Sousa I, et al. Leishmania donovani Nucleoside Hydrolase Terminal Domains in Cross-Protective Immunotherapy Against Leishmania amazonensis Murine Infection. Front Immunol. 2014;5:273doi: 10.3389/fimmu.2014.00273.
Nico, D., Gomes, D. C., Palatnik-de-Sousa, I., Morrot, A., Palatnik, M., & Palatnik-de-Sousa, C. B. (2014). Leishmania donovani Nucleoside Hydrolase Terminal Domains in Cross-Protective Immunotherapy Against Leishmania amazonensis Murine Infection. Frontiers in immunology, 5273. https://doi.org/10.3389/fimmu.2014.00273
Nico, Dirlei, et al. "Leishmania donovani Nucleoside Hydrolase Terminal Domains in Cross-Protective Immunotherapy Against Leishmania amazonensis Murine Infection." Frontiers in immunology vol. 5 (2014): 273. doi: https://doi.org/10.3389/fimmu.2014.00273
Nico D, Gomes DC, Palatnik-de-Sousa I, Morrot A, Palatnik M, Palatnik-de-Sousa CB. Leishmania donovani Nucleoside Hydrolase Terminal Domains in Cross-Protective Immunotherapy Against Leishmania amazonensis Murine Infection. Front Immunol. 2014 Jun 11;5:273. doi: 10.3389/fimmu.2014.00273. eCollection 2014. PMID: 24966857; PMCID: PMC4052736.
Copy Download .nbib Format: NLM
Share it on

Front Immunol. 2014 Jun 11;5:273. doi: 10.3389/fimmu.2014.00273. eCollection 2014.

Leishmania donovani Nucleoside Hydrolase Terminal Domains in Cross-Protective Immunotherapy Against Leishmania amazonensis Murine Infection.

Frontiers in immunology

Dirlei Nico, Daniele Crespo Gomes, Iam Palatnik-de-Sousa, Alexandre Morrot, Marcos Palatnik, Clarisa Beatriz Palatnik-de-Sousa

Affiliations

  1. Laboratório de Biologia e Bioquímica de Leishmania, Departamento de Microbiologia Geral, Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro , Rio de Janeiro , Brazil.
  2. Programa de Pós Graduação em Metrologia, Laboratório de Biometrologia, Pontifícia Universidade Católica do Rio de Janeiro , Rio de Janeiro , Brazil.
  3. Laboratório de Imunologia, Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro , Rio de Janeiro , Brazil.
  4. Programa de Pós Graduação em Clínica Médica, Faculdade de Medicina, Universidade Federal do Rio de Janeiro , Rio de Janeiro , Brazil.

PMID: 24966857 PMCID: PMC4052736 DOI: 10.3389/fimmu.2014.00273

Abstract

Nucleoside hydrolases of the Leishmania genus are vital enzymes for the replication of the DNA and conserved phylogenetic markers of the parasites. Leishmania donovani nucleoside hydrolase (NH36) induced a main CD4(+) T cell driven protective response against L. chagasi infection in mice which is directed against its C-terminal domain. In this study, we used the three recombinant domains of NH36: N-terminal domain (F1, amino acids 1-103), central domain (F2 aminoacids 104-198), and C-terminal domain (F3 amino acids 199-314) in combination with saponin and assayed their immunotherapeutic effect on Balb/c mice previously infected with L. amazonensis. We identified that the F1 and F3 peptides determined strong cross-immunotherapeutic effects, reducing the size of footpad lesions to 48 and 64%, and the parasite load in footpads to 82.6 and 81%, respectively. The F3 peptide induced the strongest anti-NH36 antibody response and intradermal response (IDR) against L. amazonenis and a high secretion of IFN-γ and TNF-α with reduced levels of IL-10. The F1 vaccine, induced similar increases of IgG2b antibodies and IFN-γ and TNF-α levels, but no IDR and no reduction of IL-10. The multiparameter flow cytometry analysis was used to assess the immune response after immunotherapy and disclosed that the degree of the immunotherapeutic effect is predicted by the frequencies of the CD4(+) and CD8(+) T cells producing IL-2 or TNF-α or both. Total frequencies and frequencies of double-cytokine CD4 T cell producers were enhanced by F1 and F3 vaccines. Collectively, our multifunctional analysis disclosed that immunotherapeutic protection improved as the CD4 responses progressed from 1+ to 2+, in the case of the F1 and F3 vaccines, and as the CD8 responses changed qualitatively from 1+ to 3+, mainly in the case of the F1 vaccine, providing new correlates of immunotherapeutic protection against cutaneous leishmaniasis in mice based on T-helper TH1 and CD8(+) mediated immune responses.

Keywords: cross- immunotherapy; cutaneous leishmaniasis; diffuse cutaneous leishmaniasis; nucleoside hydrolases; recombinant vaccines; visceral leishmaniasis

References

  1. Clin Immunol. 2008 Sep;128(3):442-6 - PubMed
  2. Mol Biochem Parasitol. 2002 Apr 9;120(2):315-9 - PubMed
  3. Parasite Immunol. 1989 May;11(3):211-22 - PubMed
  4. Nature. 2002 Dec 5;420(6915):502-7 - PubMed
  5. Biochemistry. 2008 Apr 15;47(15):4418-26 - PubMed
  6. J Infect Dis. 2007 May 1;195(9):1373-80 - PubMed
  7. Lancet Infect Dis. 2011 Oct;11(10):741-9 - PubMed
  8. Int J Parasitol. 2006 Jun;36(7):757-69 - PubMed
  9. Expert Rev Vaccines. 2008 Aug;7(6):833-51 - PubMed
  10. N Engl J Med. 2012 Dec 13;367(24):2284-95 - PubMed
  11. Vaccine. 2008 Sep 15;26(39):4991-7 - PubMed
  12. J Biomed Biotechnol. 2010;2010:617521 - PubMed
  13. Trans R Soc Trop Med Hyg. 2003 May-Jun;97(3):365-8 - PubMed
  14. Vaccine. 2008 Apr 24;26(18):2211-24 - PubMed
  15. Vaccine. 2000 Dec 8;19(9-10):1082-92 - PubMed
  16. Vaccine. 2001 Apr 30;19(23-24):3104-15 - PubMed
  17. Immunity. 2008 Aug 15;29(2):295-305 - PubMed
  18. Vet Immunol Immunopathol. 2011 May 15;141(1-2):64-75 - PubMed
  19. Vaccine. 2007 Aug 14;25(33):6176-90 - PubMed
  20. Drug Discov Today. 2003 Oct 15;8(20):934-43 - PubMed
  21. Vaccine. 2009 Feb 11;27(7):1008-17 - PubMed
  22. Hum Immunol. 2013 Dec;74(12):1491-500 - PubMed
  23. Am J Trop Med Hyg. 2007 Dec;77(6):1060-5 - PubMed
  24. Trans R Soc Trop Med Hyg. 2010 Jan;104(1):1-2 - PubMed
  25. Nature. 2006 Jun 15;441(7095):890-3 - PubMed
  26. J Biol Chem. 1999 Jul 23;274(30):21114-20 - PubMed
  27. Parasite. 2009 Sep;16(3):227-30 - PubMed
  28. Front Immunol. 2012 May 15;3:99 - PubMed
  29. An Acad Bras Cienc. 2003 Dec;75(4):443-68 - PubMed
  30. Vaccine. 2009 Nov 23;27(50):7036-45 - PubMed
  31. PLoS Negl Trop Dis. 2012;6(5):e1622 - PubMed
  32. J Immunol. 2005 Jun 1;174(11):7147-53 - PubMed
  33. J Infect Dis. 2012 Mar 1;205(5):853-63 - PubMed
  34. Nat Rev Immunol. 2008 Apr;8(4):247-58 - PubMed
  35. Vaccine. 2009 Jun 2;27(27):3505-12 - PubMed
  36. Vaccine. 2004 Jun 2;22(17-18):2234-43 - PubMed
  37. Vaccine. 2006 May 1;24(18):3909-20 - PubMed
  38. Proc Natl Acad Sci U S A. 2007 May 29;104(22):9375-80 - PubMed
  39. Vet Parasitol. 2006 Dec 20;142(3-4):271-80 - PubMed
  40. Front Immunol. 2014 May 01;5:189 - PubMed
  41. J Infect Dis. 2008 Jun 15;197(12):1762-71 - PubMed
  42. Vaccine. 2006 May 29;24(22):4863-73 - PubMed
  43. PLoS Negl Trop Dis. 2010 Nov 09;4(11):e866 - PubMed
  44. Vaccine. 2006 Mar 20;24(13):2423-31 - PubMed
  45. PLoS Negl Trop Dis. 2012;6(4):e1627 - PubMed
  46. PLoS One. 2012;7(5):e35671 - PubMed
  47. J Virol. 2003 Apr;77(8):4911-27 - PubMed
  48. Vet Immunol Immunopathol. 2010 Jun 15;135(3-4):296-302 - PubMed
  49. Rev Soc Bras Med Trop. 2006 Jan-Feb;39(1):14-21 - PubMed
  50. Trop Med Int Health. 2001 Nov;6(11):849-54 - PubMed
  51. Gene. 2001 Dec 12;280(1-2):153-62 - PubMed
  52. Malar J. 2011 Aug 04;10:224 - PubMed
  53. Nat Med. 2007 Jul;13(7):843-50 - PubMed
  54. Biochim Biophys Acta. 2009 Jun;1794(6):953-60 - PubMed
  55. Vaccine. 2008 Mar 25;26(14):1709-24 - PubMed
  56. Am J Trop Med Hyg. 2012 Oct;87(4):663-70 - PubMed
  57. PLoS Negl Trop Dis. 2012;6(12):e1947 - PubMed
  58. Clin Diagn Lab Immunol. 2002 Mar;9(2):251-6 - PubMed
  59. Parasite Immunol. 2000 Feb;22(2):73-9 - PubMed
  60. Int J Epidemiol. 1986 Dec;15(4):572-80 - PubMed
  61. BMC Infect Dis. 2013 Nov 09;13:529 - PubMed
  62. J Infect Dis. 1989 Jul;160(1):104-15 - PubMed
  63. Parasitology. 2006;133 Suppl:S87-112 - PubMed
  64. PLoS Pathog. 2012;8(7):e1002827 - PubMed
  65. Rev Soc Bras Med Trop. 2013 Nov-Dec;46(6):741-5 - PubMed
  66. Mem Inst Oswaldo Cruz. 2005 Aug;100(5):525-34 - PubMed
  67. Infect Immun. 2005 Feb;73(2):812-9 - PubMed
  68. Vaccine. 2010 Jan 8;28(3):597-603 - PubMed
  69. Rev Soc Bras Med Trop. 1996 Mar-Apr;29(2):153-63 - PubMed
  70. Lancet. 2000 Nov 4;356(9241):1565-9 - PubMed

Publication Types